Molecular Subtype
Hormone Receptor-Positive Breast Carcinoma
CI-CAN-00005524Explore in graph →
36 active trials1 approved drugs
- NCIt
- C157056
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00005524Explore in graph →
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (14)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 433 | BeOne MedicinesINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer |
| active not recruiting |
| Phase 1 |
| 24 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Sep 8, 2026 |
| clinicaltrials |
| NCT07596212 | BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder | not yet recruiting | Phase 1 / Phase 2 | 100 | University of Illinois at ChicagoOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05098210 | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer | recruiting | Phase 1 | 28 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07137416 | Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer | recruiting | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06745804 | Study of 68Ga-R10602 | completed | Phase 1 | 27 | Radionetics OncologyINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07590583 | Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial | not yet recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | completed | Phase 1 / Phase 2 | 153 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | May 11, 2026 | clinicaltrials |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | terminated | Phase 1 / Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04481113 | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | completed | Phase 1 | 8 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 3, 2025 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT03251378 | A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers | completed | Phase 1 | 129 | Hutchison Medipharma LimitedINDUSTRY | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | terminated | Phase 1 | 52 | ExelixisINDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT02152943 | Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients | completed | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2020 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials